Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B. Bertrand F, et al. Among authors: colacios c. Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7. Nat Commun. 2017. PMID: 29273790 Free PMC article.
[Anti-TNFα antibodies in melanoma immunotherapy].
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. Montfort A, et al. Among authors: colacios c. Med Sci (Paris). 2018 Oct;34(10):788-791. doi: 10.1051/medsci/2018202. Epub 2018 Nov 19. Med Sci (Paris). 2018. PMID: 30451663 Free article. French. No abstract available.
The TNF Paradox in Cancer Progression and Immunotherapy.
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. Montfort A, et al. Among authors: colacios c. Front Immunol. 2019 Jul 31;10:1818. doi: 10.3389/fimmu.2019.01818. eCollection 2019. Front Immunol. 2019. PMID: 31417576 Free PMC article. Review. No abstract available.
Anti-TNF, a magic bullet in cancer immunotherapy?
Montfort A, Dufau C, Colacios C, Andrieu-Abadie N, Levade T, Filleron T, Delord JP, Ayyoub M, Meyer N, Ségui B. Montfort A, et al. Among authors: colacios c. J Immunother Cancer. 2019 Nov 14;7(1):303. doi: 10.1186/s40425-019-0802-y. J Immunother Cancer. 2019. PMID: 31727152 Free PMC article.
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.
Imbert C, Montfort A, Fraisse M, Marcheteau E, Gilhodes J, Martin E, Bertrand F, Marcellin M, Burlet-Schiltz O, Peredo AG, Garcia V, Carpentier S, Tartare-Deckert S, Brousset P, Rochaix P, Puisset F, Filleron T, Meyer N, Lamant L, Levade T, Ségui B, Andrieu-Abadie N, Colacios C. Imbert C, et al. Among authors: colacios c. Nat Commun. 2020 Jan 23;11(1):437. doi: 10.1038/s41467-019-14218-7. Nat Commun. 2020. PMID: 31974367 Free PMC article.
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.
Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, Junior NF, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B. Montfort A, et al. Among authors: colacios c. Cancer Immunol Res. 2021 May;9(5):568-582. doi: 10.1158/2326-6066.CIR-20-0342. Epub 2021 Mar 16. Cancer Immunol Res. 2021. PMID: 33727246 Free PMC article.
TNF-R1, an immune checkpoint in melanoma?
Bertrand F, Colacios C, Ségui B. Bertrand F, et al. Among authors: colacios c. Genes Cancer. 2015 Sep;6(9-10):369-70. doi: 10.18632/genesandcancer.81. Genes Cancer. 2015. PMID: 26622939 Free PMC article. No abstract available.
29 results